Survey of macrolide-resistant Mycoplasma pneumoniae in children with community-acquired pneumonia in Switzerland by Meyer Sauteur, Patrick M et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
Survey of macrolide-resistant Mycoplasma pneumoniae in children with
community-acquired pneumonia in Switzerland
Meyer Sauteur, Patrick M; Bleisch, Barbara; Voit, Antje; Maurer, Florian P; Relly, Christa; Berger,
Christoph; Nadal, David; Bloemberg, Guido V
Abstract: Unspecified
DOI: 10.4414/smw.2014.14041
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-99690
Published Version
Originally published at:
Meyer Sauteur, Patrick M; Bleisch, Barbara; Voit, Antje; Maurer, Florian P; Relly, Christa; Berger,
Christoph; Nadal, David; Bloemberg, Guido V (2014). Survey of macrolide-resistant Mycoplasma
pneumoniae in children with community-acquired pneumonia in Switzerland. Swiss Medical Weekly,
144:w14041. DOI: 10.4414/smw.2014.14041
Peer reviewed letter | Published 25 September 2014, doi:10.4414/smw.2014.14041
Cite this as: Swiss Med Wkly. 2014;144:w14041
Survey of macrolide-resistant Mycoplasma pneumoniae
in children with community-acquired pneumonia in
Switzerland
Patrick M. Meyer Sauteura, Barbara Bleischa, Antje Voitb, Florian P. Maurerb, Christa Rellya, Christoph Bergera, David Nadala,
Guido V. Bloembergb
a Division of Infectious Diseases and Hospital Epidemiology, and Children’s Research Center (CRC), University Children’s Hospital of Zurich, Zurich,
Switzerland
b Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
Introduction
Mycoplasma pneumoniae is a leading cause of community-
acquired pneumonia (CAP) in children and macrolides are
recommended for this entity [1]. Extensive macrolide use
led to the rapid, worldwide emergence of macrolide-resist-
ant M. pneumoniae (MRMP) [2] with rates of over 90%
in Asia (China, 2012 [3]) and up to 26% in Europe (Italy,
2010 [4]). The first two cases of MRMP in Switzerland
were reported in adults in 2012 [5]. We aimed to assess the
presence of MRMP in children with CAP.
Methods
Mycoplasma pneumoniae strains detected by real-time
polymerase chain reaction (RT-PCR) in respiratory spe-
cimens (pharyngeal swab, sputum, nasopharyngeal or
tracheal secretion, bronchoalveolar lavage, or pleural as-
pirate) were investigated for macrolide resistance by se-
quence analysis of the M. pneumoniae 23S rRNA gene.
All respiratory specimens were collected from both in-pa-
tients and out-patients ≤16 years of age with clinically dia-
gnosed CAP at the University Children's Hospital of Zurich
between January 2011 and December 2013. Isolation of M.
pneumoniae chromosomal DNA and RT-PCR targeting the
P1 adhesion protein gene (P1 gene) was performed on all
respiratory specimens as previously described [6, 7]. Am-
plification of the partial M. pneumoniae 23S rRNA gene
(domain V) followed by sequence analysis for the detec-
tion of resistance mutations at positions 2063, 2064, and
2617 was conducted on M. pneumoniae RT-PCR-positive
samples according to Matsuoka et al. [8]. Clinical data was
gathered from medical records.
Abbreviations
CAP = Community-acquired pneumonia
DNA = Deoxyribonucleic acid
MRMP = Macrolide-resistant Mycoplasma pneumoniae
rRNA = Ribosomal ribonucleic acid
RT-PCR = Real-time polymerase chain reaction
Results
During the 3 years, respiratory specimens from 50 out of
241 CAP patients (20.7%; figure) tested positive for M.
pneumoniae. The median age of the 50 patients was 9.1
years (range, 1.3–15.9). The clinical diagnosis of CAP was
radiologically confirmed in 93% (43/46). Macrolides were
administered in 2% of patients before and in 26% after de-
tection of M. pneumoniae.
Sequencing of the partial 23S rRNA gene amplicons from
these M. pneumoniae RT-PCR-positive respiratory samples
(96% pharyngeal swabs) revealed one sample with an
A2063G mutation, which confers high-level macrolide res-
istance [2]. Mutations at position 2064 or 2617 were not
found. The resistant strain was detected in a pharyngeal
swab specimen of an otherwise healthy 7-year-old boy seen
in September 2013 with a mild and self-limiting M. pneu-
moniae CAP (no hospitalisation nor antimicrobial treat-
ment). The patient had not received prior antimicrobial
treatment.
Figure
Case distribution of children with community-acquired pneumonia
(CAP) investigated for Mycoplasma pneumoniae by real-time
polymerase chain reaction (RT-PCR) in respiratory specimens (n =
241) during the study period between 2011 and 2013.
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Discussion
Our survey documents the first existence of MRMP in a
child with CAP due to M. pneumoniae in Switzerland. We
detected the A2063G mutation that represents the most
common cause of high-level macrolide resistance in M.
pneumoniae [2]. At least four mutations in the 23S rRNA
gene of M. pneumoniae have been reported in vitro,
whereby mutations at positions 2063, 2064, and 2617 (cor-
responding to Escherichia coli 23S rRNA gene positions
2058, 2059, and 2611) were also found in vivo [2]. The
point mutation results in modification of the peptidyltrans-
ferase loop of domain V of 23S rRNA, which reduces the
binding affinity of macrolides to the 23S rRNA component
of the large subunit (50S) of the bacterial ribosome.
The frequency of MRMP among our paediatric CAP pa-
tients (2.0%, 1/50) is remarkably low compared to that re-
cently detected in children in Japan (87.1%, 176/202) [9]
and China (97.0%, 32/33) [3] although study designs and
cohorts differ, which limits comparison. The high resist-
ance rate in Asia is linked with broad macrolide use [2].
This may be also true for the alarming resistance rate ob-
served in the neighbouring country Italy (25.6%, 11/43)
[4], where selective antibiotic pressure has been demon-
strated to lead to de novo macrolide resistance during treat-
ment. However, the emergence of MRMP in our study
parallels the lower occurrence of MRMP in other neigh-
bouring countries, e.g., Germany (1.2%, 2/167) [10] and
France (9.8%, 5/51) [11]. There was no macrolide treat-
ment history in our patient. This suggests MRMP did not
emerge in the patient himself but rather was acquired from
the community. Importantly, children have recently been
recognised to carry M. pneumoniae in their respiratory tract
in up to 21% [12]. This influences current diagnostic pro-
cedures, because neither PCR nor single sample serology
is a reliable indicator of infection [1, 12], and, in turn, may
suggest that MRMP is indeed considerably less frequent in
Switzerland compared to in countries with higher prescrip-
tion numbers of macrolides, as e.g., Asia [3, 9].
Limitations of our survey include the retrospective design
(missing M. pneumoniae CAP cases not tested for M. pneu-
moniae and/or managed by general practitioners only), the
patient cohort (both in-patients and out-patients) that was
geographically confined to the region of Zurich, Switzer-
land, and the lack of control samples from asymptomatic
children. Moreover, RT-PCR for M. pneumoniae from res-
piratory specimens other than pharyngeal swabs is less val-
idated.
MRMP can potentially have clinical consequences, i.e.,
longer duration of symptoms and hospitalisation, more
severe CAP, and increased frequency of extrapulmonary
manifestations [1]. Thus, further surveys of MRMP in chil-
dren should be considered also in Switzerland to prevent
missing changes in MRMP in the local community. Our
results are compatible with the rather judicious prescription
of macrolides in Switzerland [13]. To this effect current
guidelines confine macrolide treatment for CAP in children
at any age as second choice if there is no response to first-
line empirical β-lactam antibiotics or in the case of very
severe CAP [14].
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Figure
Case distribution of children with community-acquired pneumonia (CAP) investigated for Mycoplasma pneumoniae by real-time polymerase
chain reaction (RT-PCR) in respiratory specimens (n = 241) during the study period between 2011 and 2013.
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